Advanced search
Publication Cover
Modern Rheumatology Volume 30, 2020 - Issue 3
Journal homepage
6,748
Views
27
CrossRef citations to date
0
Altmetric
Review Article

Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update

Ichiro KobayashiCenter for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center, Sapporo, Japan; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-4956-4010View further author information
ORCID Icon,
Shinji AkiokaDepartment of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan; View further author information
,
Norimoto KobayashiDepartment of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan; View further author information
,
Naomi IwataDepartment of Infection and Immunology, Aichi Children’s Health and Medical Center, Obu, Japan; View further author information
,
Shunichiro TakezakiDepartment of Pediatrics, Hokkaido University Hospital, Sapporo, Japan; View further author information
,
Haruna NakasekoDepartment of Infection and Immunology, Aichi Children’s Health and Medical Center, Obu, Japan; View further author information
,
Satoshi SatoDivision of Infectious Disease and Immunology, Saitama Children’s Medical Center, Omiya, Japan; View further author information
,
Yutaka NishidaDepartment of Pediatrics, School of Medicine, Gunma University, Maebashi, Japan; View further author information
,
Tomo NozawaDepartment of Pediatrics, School of Medicine, Yokohama City University, Yokohama, Japan; View further author information
,
Yuichi YamasakiDepartment of Pediatrics, Kagoshima University Hospital, Kagoshima, Japan; View further author information
,
Kazuko YamazakiDepartment of Pediatrics, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan; View further author information
,
Satoru AraiDepartment of Dermatology, St. Luke’s International Hospital, Tokyo, Japan; View further author information
,
Ichizo NishinoDepartment of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; View further author information
&
Masaaki MoriLifetime Clinical Immunology, Tokyo Medical and Dental University, Tokyo, JapanView further author information
 show all
Pages 411-423 | Received 01 Nov 2018, Accepted 03 Jan 2020, Published online: 03 Feb 2020

References

  • Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631):2201–12.
  • Fujikawa S, Okuni M. A nationwide surveillance study of rheumatic diseases among Japanese children. Acta Paediatr Jpn. 1997;39(2):242–4.
  • Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76:329–40.
  • Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, on behalf of UK Juvenile Dermatomyositis Research Group, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther. 2014;16(4):R138–8.
  • Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med. 2016;280(1):24–38.
  • Ueki M, Kobayashi I, Takezaki S, Tozawa Y, Okura Y, Yamada M, et al. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies. Mod Rheumatol. 2018;9:1–6.
  • Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292(7):344–7.
  • Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systemic review of juvenile onset clinically amyopathic dermatomyositis. Br J Dermatol. 2007;157(4):637–44.
  • Chen S, Wang Q, Wu Z, Li Y, Li P, Sun F, et al. Genetic association study of TNFAIP3, IFIH1, IRF5 polymorphisms with polymyositis/dermatomyositis in Chinese Han population. PLoS One. 2014;9(10):e110044.
  • Werth VP, Berlin JA, Callen JP, Mick R, Sullivan KE. Mannose binding lectin (MBL) polymorphisms associated with low MBL production in patients with dermatomyositis. J Invest Dermatol. 2002;119(6):1394–9.
  • Miller FW, Cooper RG, Vencovský J, Rider LG, Danko K, Wedderburn LR, with the Myositis Genetics Consortium, et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum. 2013;65(12):3239–47.
  • Uruha A, Suzuki S, Nishino I. Diagnosis of dermatomyositis: autoantibody profile and muscle pathology. Clin Exp Neuroimmunol. 2017;8(4):302–12.
  • Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 1995;22(4):668–74.
  • Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955–64.
  • Quinter SD, Chiu YE, Lyon VB, Holland KE, Ruggeri SY, Drolet BA. Inverse Gottron’s papules: an unusual cutaneous manifestation of juvenile dermatomyositis. Pediatr Dermatol. 2012;29(5):641–4.
  • Peloro TM, Miller OF, Hahn TF, Newman ED. Juvenile dermatomyositis: a retrospective review of a 30-year experience. J Am Acad Dermatol. 2001;45(1):28–34.
  • Saini I, Kalaivani M, Kabra SK. Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. Rheumatol Int. 2016;36(7):961–5.
  • Stahl NI, Klippel JH, Decker JL. A cutaneous lesion associated with myositis. Ann Intern Med. 1979;91(4):577–9.
  • Yokoyama T, Shimizu M, Ishikawa S, Ueno K, Hamaguchi Y, Takehara K, et al. Accumulation of mature B cells in the inflamed muscle tissue of a patient with anti-155/140 antibody-positive juvenile dermatomyositis. Modern Rheumatol. 2013;23(1):167–71.
  • Brown VE, Pilkington CA, Feldman BM, Davidson JE. Network for Juvenile Dermatomyositis, Paediatric Rheumatology European Society (PReS). An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology. 2006;45(8):990–3.
  • Rider LG, Miller FW. Laboratory evaluation of the inflammatory myopathies. Clin Diagn Lab Immunol. 1995;2(1):1–9.
  • Oddis CV, Medsger TA Jr. Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis. J Rheumatol. 1988;15:807–11.
  • Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(1):25–41.
  • Kishi T, Miyamae T, Hara R, Nakajima S, Imagawa T, Mori M, et al. Clinical analysis of 50 children with juvenile dermatomyositis. Mod Rheumatol. 2013;23(2):311–7.
  • Sato JO, Sallum AM, Ferriani VP, Marini R, Sacchetti SB, Okuda EM, Rheumatology Committee of the São Paulo Paediatrics Society, et al. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol. 2009;27(6):1031–8.
  • Bowyer SL, Ragsdale CG, Sullivan DB. Factor VIII related antigen and childhood rheumatic diseases. J Rheumatol. 1989;16(8):1093–7.
  • Bloom BJ, Tucker LB, Miller LC, Schaller JG. von Willebrand factor in juvenile dermatomyositis. J Rheumatol. 1995;22(2):320–5.
  • Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol. 2004;31(8):1644–9.
  • Rider LG, Lie L, Chipman J, Costello R, O’Hanlon T, Fleisher T, et al. Biomarkers of juvenile dermatomyositis (JDM) aid in assessing disease activity over enzyme alone. Arthritis Rheum. 2009;60(Suppl, 10):1–40.
  • Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai R, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology. 2015;54(5):784–91.
  • De Benedetti F, De Amici M, Aramini L, Ruperto N, Martini A. Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. Arch Dis Child. 1993;69(2):232–5.
  • Rider LG, Schiffenbauer AS, Zito M, Lim KL, Ahmed A, Zemel LS, Juvenile Dermatomyositis Disease Activity Collaboration Study Group, et al. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin Chem. 2002;48(10):1681–8.
  • Kobayashi I, Ono S, Kawamura N, Okano M, Kobayashi K. Elevated serum levels of soluble interleukin-2 receptor in juvenile dermatomyositis. Pediatr Int. 2001;43(1):109–11.
  • Kobayashi I, Ono S, Kawamura N, Okano M, Miyazawa K, Shibuya H, et al. KL-6 is a potential marker for interstitial lung disease associated with juvenile dermatomyositis. J Pediatr. 2001;138(2):274–6.
  • Iwata N, Nakaseko H, Kohagura T, Yasuoka R, Abe N, Kawabe S, et al. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: experience at a single center in Japan. Mod Rheumatol. 2018;10:1–15.
  • Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr. 2011;158(4):675–7.
  • Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193–200.
  • Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49(3):433–40.
  • Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016;25(8):925–33.
  • Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016;280(1):8–23.
  • Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H, for the Juvenile Dermatomyositis Research Group UK, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology. 2007;47(3):324–8.
  • Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012;64(2):513–22.
  • Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology. 2014;53(12):2204–8.
  • Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, Juvenile Dermatomyositis Research Group, UK and Ireland, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009;60(6):1807–14.
  • Hernandez RJ, Sullivan DB, Chenevert TL, Keim DR. MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings. AJR Am J Roentgenol. 1993;161(2):359–66.
  • Malattia C, Damasio MB, Madeo A, Pistorio A, Providenti A, Pederzoli S, et al. Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. Ann Rheum Dis. 2014;73(6):1083–90.
  • Summers RM, Brune AM, Choyke PL, Chow CK, Patronas NJ, Miller FW, et al. Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery imaging. Radiology. 1998;209(1):191–6.
  • Kimball AB, Summers RM, Turner M, Dugan EM, Hicks J, Miller FW, et al. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. Arthritis Rheum. 2000;43(8):1866–73.
  • Sakurai N, Hino-Shishikura A, Nozawa T, Kamide H, Ohara A, Nishimura K, et al. Clinical significance of subcutaneous fat and fascial involvement in juvenile dermatomyositis. Mod Rheumatol. 2019;29(5):808–13.
  • Keim DR, Hernandez RJ, Sullivan DB. Serial magnetic resonance imaging in juvenile dermatomyositis. Arthritis Rheum. 2010;34(12):1580–4.
  • Maillard SM, Jones R, Owens C, Pilkington C, Woo P, Wedderburn LR, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology. 2004;43(5):603–8.
  • Davis WR, Halls JE, Offiah AC, Pilkington C, Owens CM, Rosendahl K. Assessment of active inflammation in juvenile dermatomyositis: a novel magnetic resonance imaging-based scoring system. Rheumatology. 2011;50(12):2237–44.
  • Van De Vlekkert J, Maas M, Hoogendijk JE, De Visser M, Van Schaik IN. Combining MRI and muscle biopsy improves diagnostic accuracy in subacute-onset idiopathic inflammatory myopathy. Muscle Nerve. 2015;51(2):253–8.
  • Wedderburn LR, Varsani H, Li CK, Newton KR, Amato AA, Banwell B, UK Juvenile Dermatomyositis Research Group, et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum. 2007;57(7):1192–201.
  • Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(5):337–45.
  • Uruha A, Nishikawa A, Tsuburaya RS, Hamanaka K, Kuwana M, Watanabe Y, et al. Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology. 2017;88(5):493–500.
  • Whitaker JN, Engel WK. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N Engl J Med. 1972;286(7):333–8.
  • Lopez De Padilla CM, Vallejo AN, Lacomis D, McNallan K, Reed AM. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum. 2009;60:1160–72.
  • Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984;16(2):193–208.
  • Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol. 1984;16(2):209–15.
  • Lopez de Padilla CM, Vallejo AN, McNallan KT, Vehe R, Smith SA, Dietz AB, et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum. 2007;56:1658–68.
  • Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17(12):72.
  • Uruha A, Suzuki S, Suzuki N, Nishino I. Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1. Brain. 2016;139(9):e50.
  • Whittaker RG. The fundamentals of electromyography. Pract Neurol. 2012;12(3):187–94.
  • Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Assessment Tool (CAT), Dermatomyosities Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res. 2011;63(Suppl 1):S118–S57.
  • Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res. 2010;62(4):465–72.
  • Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, in cooperation with The Juvenile Dermatomyositis Disease Activity Collaborative Study Group, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum. 1999;42(10):2213–9.
  • Quiñones R, Morgan GA, Amoruso M, Field R, Huang CC, Pachman LM. Lack of achievement of a full score on the childhood myositis assessment scale by healthy four-year-olds and those recovering from juvenile dermatomyositis. Arthritis Care Res. 2013;65(10):1697–701.
  • Disease Activity Core Set Measures. [last accessed 22 Jan 2020]. Available from: http://www.niehs.nih.gov/research/resources/imacs/diseaseactivity/index.cfm
  • Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum. 2008;59:4–13.
  • Sultan SM, Allen E, Oddis CV, Kiely P, Cooper RG, Lundberg IE, et al. Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum. 2008;58(11):3593–9.
  • Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, for the Paediatric Rheumatology International Trials Organisation (PRINTO), et al. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis. 2013;72(5):686–93.
  • Almeida B, Campanilho-Marques R, Arnold K, Pilkington CA, Wedderburn LR, Nistala K, Juvenile Dermatomyositis Research Group. Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated. Arthritis Rheumatol. 201(67):2495–502.
  • Tansley SL, Betteridge ZE, McHugh NJ. The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol. 2013;25(6):772–7.
  • Godfrey R, Quinlivan R. Skeletal muscle disorders of glycogenolysis and glycolysis. Nat Rev Neurol. 2016;12(7):393–402.
  • Rubio-Gozalbo ME, Bakker JA, Waterham HR, Wanders RJA. Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects. Mol Aspects Med. 2004;25(5–6):521–32.
  • Zürcher RM, Horber FF, Grünig BE, Frey FJ. Effect of thyroid dysfunction on thigh muscle efficiency. J Clin Endocrinol Metab. 1989;69(5):1082–6.
  • Kanazawa N. Nakajo–Nishimura syndrome: an autoinflammatory disorder showing pernio-like rashes and progressive partial lipodystrophy. Allergol Int. 2012;61(2):197–206.
  • Thyss A, el Baze P, Lefebvre JC, Schneider M, Ortonne JP. Dermatomyositis-like syndrome in X-linked hypogammaglobulinemia. Case-report and review of the literature . Acta Derm Venereol. 1990;70(4):309–13.
  • Sullivan DB, Cassidy JT, Petty RE, Burt A. Prognosis in childhood dermatomyositis. J Pediatr. 1972;80(4):555–63.
  • Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr. 1983;103(6):882–8.
  • Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47(4):505–11.
  • Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res. 2010;62(1):63–72.
  • Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol. 2000;19(2):138–41.
  • Laxer RM, Stein LD, Petty RE. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum. 1987;30(3):328–34.
  • Seshadri R, Feldman BM, Ilowite N, Cawkwell G, Pachman LM. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum. 2008;59(7):989–95.
  • Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52(11):3570–8.
  • Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children’s Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res. 2010;62:219–25.
  • Miller LC, Sisson BA, Tucker LB, DeNardo BA, Schaller JG. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum. 1992;35(10):1143–9.
  • Kobayashi I, Mori M, Yamaguchi K-i, Ito S, Iwata N, Masunaga K, et al. Pediatric Rheumatology Association of Japan (PRAJ) recommendation for vaccination in pediatric rheumatic diseases. Mod Rheumatic. 2015;25(3):335–43.
  • Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatol Treat. 2004;15(1):35–9.
  • Garcia-Doval I, Cruces M. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients. Dermatology. 2004;209:247–8.
  • Tabarki B, Ponsot G, Prieur AM, Tardieu M. Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids. Eur J Paediatr Neurol. 1998;2(4):205–11.
  • Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomized trial. Lancet. 2016;387(10019):671–8.
  • Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med. 1980;92(3):365–9.
  • Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum. 1981;24(1):45–8.
  • Heckmatt J, Hasson N, Saunders C, Thompson N, Peters AM, Cambridge G, et al. Cyclosporin in juvenile dermatomyositis. Lancet. 1989;1:1063–6.
  • Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, et al. Preliminary evidence for cyclosporine A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol. 1997;24(12):2436–43.
  • Kobayashi I, Yamada M, Takahashi Y, Kawamura N, Okano M, Sakiyama Y, et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporine A. Rheumatology (Oxford). 2002;42(2):371–4.
  • Hssan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol. 2008;27:1469–71.
  • Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res. 2010;62(10):1446–51.
  • Dagher R, Desjonquères M, Duquesne A, Quartier P, Bader-Meunier B, Fischbach M, et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int. 2012;32(3):711–6.
  • Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol. 2000;27(10):2498–503.
  • Dalakas MC, Illa I, Dambrosia JM, Stein DP, Otero C, Dinsmore ST, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993–2000.
  • Lam CG, Manlhiot C, Pullenayegum EM, Feldman EM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis. 2011;70(12):2089–94.
  • Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004;43(4):491–6.
  • Deakin CT, Campanilho-Marques R, Simou S, Moraitis E, Wedderburn LR, Pullenayegum E, the Juvenile Dermatomyositis Research Group, et al. Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modeling. Arthritis Rheumatol. 2018;70(5):785–93.
  • Green DM, Liu W, Kutteh WH, Ke RW, Shelton KC, Sklar CA, et al. Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. Lancet Oncol. 2014;15(11):1215–23.
  • Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, the RIM Study Group, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–24.
  • Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38(7):1436–40.
  • Dau PC. Plasma exchange in polymyositis and dermatomyositis. N Engl J Med. 1992;327(14):1030–1.
  • Momomura M, Miyamae T, Nozawa T, Kikuchi M, Kizawa T, Imagawa T, et al. Serum levels of anti-SRP54 antibodies reflect disease activity of necrotizing myopathy in a child treated effectively with combinatorial methylprednisolone pulses and plasma exchanges followed by intravenous cyclophosphamide. Mod Rheumatol. 2014;24(3):529–31.
  • Huber AM, Robinson AB, Reed AM, Abramson L, Bout-Tabaku S, Carrasco R, Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance, et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res. 2012;64(4):546–53.
  • Giancane G, Lavarello C, Pistorio A, Oliveira SK, Zulian F, Cuttica R, for the Paediatric Rheumatology International Trials Organisation (PRINTO), et al. The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients. Pediatr Rheumatol. 2019;17(1):24.
  • Marie I, Hachulla E, Chérin P, Hellot MF, Herson S, Levesque H, et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum. 2005;15(53):155–65.
  • Migita K, Sasaki Y, Ishizuka N, Arai T, Kiyokawa T, Suematsu E, et al. Glucocorticoid therapy and the risk of infection in patients with newly diagnosed autoimmune disease. Medicine. 2013;92(5):285–93.
  • Stewart WA, Acott PD, Salisbury SR, Lang BA. Bone mineral density in juvenile dermatomyositis: assessment using dual x-ray absorptiometry. Arthritis Rheum. 2003;48(8):2294–8.
  • Lee CW, Muo CH, Liang JA, Sung FC, Hsu CY, Kao CH. Increased osteoporosis risk in dermatomyositis or polymyositis independent of the treatments: a population-based cohort study with propensity score. Endocrine. 2016;52(1):86–92.
  • Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab. 2014;32(4):337–50.
  • Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni A, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum. 2000;43(9):1960–6.
  • Yokota S. The Ministry of Health, Labour and Welfare of Japan Study Group Report on Severe Pediatric Rheumatic Disease. Tokyo: Ministry of Health, Labour and Welfare; 2010 (in Japanese).
  • Sanner H, Aalokken TM, Gran JT, Sjaastad I, Johansen B, Flatø B. Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis. 2011;70(1):86–91.
  • Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen FK, Nielsen S. Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol. 2012;41(1):50–8.
  • Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011;105(9):1380–7.
  • Kurita T, Yasuda S, Oba K, Odani T, Kono M, Otomo K, et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford). 2015;54(1):39–44.
  • Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32(9):1719–26.
  • Bakewell CJ, Raghu G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest. 2011;139(2):441–3.
  • Hamada-Ode K, Taniguchi Y, Kimata T, Kawaguchi Y, Shimamura Y, Kuwana M, et al. High-dose intravenous immunoglobulin therapy for rapidly progressive interstitial pneumonitis accompanied by anti-melanoma differentiation-associated gene 5 antibody-positive amyopathic dermatomyositis. Eur J Rheumatol. 2015;2:83–5.
  • Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187(3):201–6.
  • Marie I, Dominique S, Janvresse A, Levesque H, Menard JF. Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir Med. 2012;106(4):581–7.
  • Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009;48(8):968–71.
  • Vandenbroucke E, Grutters JC, Altenburg J, Boersma WG, ter Borg EJ, van den Bosch JM. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int. 2009;29(12):1499–502.
  • Cozzani E, Cinotti E, Felletti R, Pelucco D, Rebora A, Parodi A. Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil. Immunopharmacol Immunotoxicol. 2013;35(6):687–92.
  • Hervier B, Masseau A, Mussini JM, Audrain M, Hamidou MA. Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome. Joint Bone Spine. 2009;76(5):575–6.
  • Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. 2011;63(11):3439–47.
  • Mira-Avendano IC, Parambil JG, Yadav R, Arrossi V, Xu M, Chapman JT, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med. 2013;107(6):890–6.
  • Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res. 2010;62(10):1496–501.
  • Sundaragiri PR, Vallabhajosyula S, Kanaan JP. Interstitial lung disease in antisynthetase syndrome without clinical myositis. BMJ Case Rep. 2014;2014:pii: bcr2014204296.
  • Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006;130(1):30–6.
  • Tsuchiya H, Tsuno H, Inoue M, Takahashi Y, Yamashita H, Kaneko H, et al. Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol. 2014;24(4):694–6.
  • Bozkirli DE, Kozanoglu I, Bozkirli E, Yucel E. Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis. J Clin Apheresis. 2013;28(6):422–5.
  • Omotoso BA, Ogden MI, Balogun RA. Therapeutic plasma exchange in antisynthetase syndrome with severe interstitial lung disease. J Clin Apheresis. 2015;30(6):375–9.
  • Antonelli M, Fumagalli R, Cruz DN, Brienza N, Giunta F, EUPHAS Study Group. PMX endotoxin removal in the clinical practice: results from the EUPHAS trial. Contrib Nephrol. 2010;167:83–90.
  • Ichiyasu H, Horio Y, Tsumura S, Hirosako S, Sakamoto Y, Sakata S, et al. Favorable outcome with hemoperfusion of polymyxin B-immobilized fiber column for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis: report of three cases. Mod Rheumatol. 2014;24(2):361–5.
  • Kakugawa T, Mukae H, Saito M, Ishii K, Ishimoto H, Sakamoto N, et al. Rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intern Med. 2008;47(8):785–90.
  • Teruya A, Kawamura K, Ichikado K, Sato S, Yasuda Y, Yoshioka M. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis. Chest* 2013;144(6):1934–6.
  • Al-Mayouf SM, Al-Eid W, Bahabri S, Al-Mofada S. Interstitial pneumonitis and air leakage in juvenile dermatomyositis. Rheumatology (Oxford). 2001;40:588–90.
  • Robinson AB, Hoeltzel MF, Wahezi DM, Becker ML, Kessler EA, Schmeling H, the Juvenile Myositis CARRA Subgroup, for the CARRA Registry Investigators, et al. Clinical characteristics of children with juvenile dermatomyositis: The Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care Res. 2014;66(3):404–10.
  • Balin SJ, Wetter DA, Andersen LK, Davis MD. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996–2009. Arch Dermatol. 2012;148:455–62.
  • Rider LG. Calcinosis in juvenile dermatomyositis: pathogenesis and current therapies. Pediatr Rheumatol Online J. 2003;1:2.
  • Blane CE, White SJ, Braunstein EM, Bowyer SL, Sullivan DB. Patterns of calcification in childhood dermatomyositis. Am J Roentgenol. 1984;142(2):397–400.
  • Shimizu M, Ueno K, Ishikawa S, Kasahara Y, Yachie A. Role of activated macrophage and inflammatory cytokines in the development of calcinosis in juvenile dermatomyositis. Rheumatology (Oxford). 2014;53(4):766–7.
  • Shahi V, Wetter DA, Howe BM, Ringler MD, Davis DM. Plain radiography is effective for the detection of calcinosis cutis is occurring in association with autoimmune connective tissue disease. Br J Dermatol. 2014;170(5):1073–9.
  • Oliveri MB, Palermo R, Mautalen C, Hübscher O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol. 1996;23(12):2152–5.
  • Nakagawa T, Takaiwa T. Calcinosis cutis in juvenile dermatomyositis responsive to aluminum hydroxide treatment. J Dermatol. 1993;20(9):558–60.
  • Wang WJ, Lo WL, Wong CK. Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminum hydroxide therapy. Arch Dermatol. 1988;124(11):1721–2.
  • Touimy M, Janani S, Rachidi W, Etaouil N, Mkinsi O. Calcinosis universalis complicating juvenile dermatomyositis: improvement after intravenous immunoglobulin therapy. Joint Bone Spine. 2013;80(1):108–9.
  • Miyamae T, Sano F, Ozawa R, Imagawa T, Inayama Y, Yokota S. Efficacy of thalidomide in a girl with inflammatory calcinosis, a severe complication of juvenile dermatomyositis. Pediatr Rheumatol. 2010;8(1):6.
  • Nakamura H, Kawakami A, Ida H, Ejima E, Origuchi T, Eguchi K. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis. J Rheumatol. 2006;33(8):1691–3.
  • Al-Mayouf SM, Alsonbul A, Alismail K. Localized calcinosis in juvenile dermatomyositis: successful treatment with intralesional corticosteroids injection. Int J Rheum Dis. 2010;13(3):e26–8.
  • Marco Puche A, Calvo Penades I, Lopez MB. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol. 2010;28(1):135–40.
  • Ambler GR, Chaitow J, Rogers M, McDonald DW, Ouvrier RA. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol. 2005;32(9):1837–9.
  • Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). 2008;47(6):877–80.
  • Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr. 2012;160(3):520–2.
  • Vitale A, Delia G, La Torre F, Calcagno G, D’Alcontres FS. Massive gluteal calcinosis in a 10-year-old girl with juvenile dermatomyositis: successful surgical management. Plast Reconstr Surg. 2009;124:e456–8.
  • Wu JJ, Metz BJ. Calcinosis cutis of juvenile dermatomyositis treated with incision and drainage. Dermatol Surg. 2008;34:575–7.
  • Kobayashi I, Kawamura N, Okano M, Sageshima S, Nakayama T, Ohyu J, et al. Thrombocytopaenia in juvenile dermatomyositis. Scand J Rheumatol. 2006;35(1):79–80.
  • Milisenda JC, Doti PI, Prieto-Gonzalez S, Grau JM. Dermatomyositis presenting with severe subcutaneous edema: five additional cases and review of the literature. Semin Arthritis Rheum. 2014;44(2):228–33.
  • Mitchell JP, Dennis GJ, Rider LG. Juvenile dermatomyositis presenting with anasarca: a possible indicator of severe disease activity. J Pediatr. 2001;138(6):942–5.
  • Karabiber H, Aslan M, Alkan A, Yakinci C. A rare complication of generalized edema in juvenile dermatomyositis: a report of one case. Brain Dev. 2004;26(4):269–72.
  • Huemer C, Kitson H, Malleson PN, Sanderson S, Huemer M, Cabral DA, et al. Lipodystrophy in patients with juvenile dermatomyositis—evaluation of clinical and metabolic abnormalities. J Rheumatol. 2001;28(3):610–5.
  • Verma S, Singh S, Bhalla AK, Khullar M. Study of subcutaneous fat in children with juvenile dermatomyositis. Arthritis Rheum. 2006;55(4):564–8.
  • Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore). 2008;87(2):70–86.
  • Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350(12):1220–34.
  • Lebasrchi J, Ajluni N, Neidert A, Oral EA. A report of three cases with acquired generalized lipodystrophy with distinct autoimmune conditions treated with metreptin. J Clin Endocrinol Metabol. 2015;100:3967–70.
  • Karaca NE, Aksu G, Yeniay BS, Kutukculer N. Juvenile dermatomyositis with a rare and remarkable complication: sinus bradycardia. Rheumatol Int. 2006;27(2):179–82.
  • Pereira RM, Lerner S, Maeda WT, Goldenstein-Schainberg C, Cossermelli W. Pericardial tamponade in juvenile dermatomyositis. Clin Cardiol. 1992;15(4):301–3.
  • Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic implicatins of histopathology in childhood polydermatomyositis. Arthritis Rheum. 1982;25(2):126–39.
  • Pachman LM, Cooke N. Juvenile dermatomypsitis: a clinical and immunologic study. J Pediatr. 1980;96(2):226–34.
  • Schwartz T, Sanner H, Husebye T, Flatø B, Sjaastad I. Cardiac dysfunction in juvenile dermatomyositis: a case-control study. Ann Rheum Dis. 2011;70(5):766–71.
  • Schwartz T, Sanner H, Gjesdal O, Flatø B, Sjaastad I. In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity. Ann Rheum Dis. 2014;73(10):1805–10.
  • Yoshimatsu Y, Kotani T, Fujiki Y, Oda K, Kataoka T, Yamairi K, et al. Successful treatment with intravenous high-dose immunoglobulin for cardiomyopathy in dermatomyositis complicated with progressive interstitial pneumonia. Int J Rheum Dis. 2019;22(2):321–4.
  • Magill HL, Hixson SD, Whitington G, Igarashi M, Hannissian A. Duodenal perforation in childhood dermatomyositis. Pediatr Radiol. 1984;14(1):28–30.
  • Mamyrova G, Kleiner DE, James-Newton L, Shaham B, Miller FW, Rider LG. Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteopathy. Arthritis Rheum. 2007;57(5):881–4.
  • Singh S, Suri D, Aulakh R, Gupta A, Rawat A, Kumar RM. Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India. Clin Rheumatol. 2014;33(11):1675–9.
  • Wang IJ, Hsu WM, Shun CT, Chiang BL, Ni YH. Juvenile dermatomyositis complicated with vasculitis and duodenal perforation. J Formos Med Assoc. 2001;100(12):844–6.
  • Marie I, Menard JF, Hatron PY, Hachulla E, Mouthon L, Tiev K, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res. 2010;62(12):1748–55.
  • Tse S, Lubelsky S, Gordon M, Al Mayouf SM, Babyn PS, Laxer RM, et al. The arthritis of inflammatory childhood myositis syndrome. J Rheumatol. 2001;28(1):192–7.
  • Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013;65(8):1307–15.
  • Yen TH, Lai PC, Chen CC, Huang JY. Renal involvement in patients with polymyositis and dermatomyositis. Clin Pract. 2005;59:188–93.
  • Xie Q, Liu Y, Liu G, Yang N, Yin G. Diffuse proliferative glomerulonephritis associated with dermatomyositis with nephrotic syndrome. Rheumatol Int. 2010;30(6):821–5.
  • Soylu A, Kavukçu S, Türkmen M, Saroğlu S. Dermatomyositis with membranous nephropathy. Turk J Pediatr. 2001;43(2):143–5.
  • Nickavar A, Mehr Azma M. Nephrotic syndrome and juvenile dermatomyositis. Rheumatol Int. 2012;32(9):2933–5.
  • Couvrat-Desvergnes G, Masseau A, Benveniste O, Bruel A, Hervier B, Mussini J-M, et al. The spectrum of involvement in patients with inflammatory myopathies. Medicine (Baltimore). 2014;93(1):33–41.
  • Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14(3):275–85.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.